GSK inks licensing deal worth up to $1B with China's Frontier Bio
Source: SeekingAlpha
2026-02-24 08:51:38 ET
More on GSK
- GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade)
- GSK plc 2025 Q4 - Results - Earnings Call Presentation
- GSK plc (GSK) Q4 2025 Earnings Call Transcript
- CDC said to delay vaccine panel meeting after lawsuit challenging its composition
- GSK says RSV shot Arexvy lowers risk of CV events, asthma, and COPD
Read the full article on Seeking Alpha
For further details see:
GSK inks licensing deal worth up to $1B with China’s Frontier Bio
Alnylam Pharmaceuticals Inc.
NASDAQ: ALNY
ALNY Trading
-0.06% G/L:
$324.10 Last:
426,542 Volume:
$323.69 Open:
ALNY Latest News
March 05, 2026 08:30:00 am
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
February 23, 2026 10:00:00 am
Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference
February 19, 2026 08:30:00 am
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
ALNY Stock Data
$42,146,950,218
131,611,785
0.16%
379
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
